Rates and impact of hepatitis on human immunodeficiency virus infection in a large African cohort

被引:33
作者
Ladep, Nimzing Gwamzhi [1 ]
Agaba, Patricia Aladi [2 ]
Agbaji, Oche [2 ]
Muazu, Auwal [2 ]
Ugoagwu, Placid [2 ]
Imade, Godwin [2 ]
Cooke, Graham [1 ]
McCormack, Sheena [3 ]
Taylor-Robinson, Simon David [1 ]
Idoko, John [2 ,4 ]
Kanki, Phyllis [5 ]
机构
[1] Univ London Imperial Coll Sci Technol & Med, Sect Hepatol, Dept Med, London W2 1NY, England
[2] Univ Jos, Teaching Hosp, AIDS Prevent Initiat Nigeria, Jos 930001, Nigeria
[3] MRC, Clin Trials Unit, London NW1 2DA, England
[4] Natl Agcy Control AIDS, Cent Business Dist, Abuja 905001, Nigeria
[5] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA
关键词
Human immunodeficiency virus; Hepatitis B; Hepatitis C; Africa; Liver disease; B SURFACE-ANTIGEN; ANTIRETROVIRAL THERAPY; C VIRUS; LIVER-DISEASE; HBV INFECTION; HIV; PREVALENCE; COINFECTION; PROGRESSION; MORTALITY;
D O I
10.3748/wjg.v19.i10.1602
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AIM: To determine the rates and impact of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections on response to long-term highly active antiretroviral therapy (HAART) in a large human immunodeficiency virus (HIV) population in Nigeria. METHODS: HBV and HCV as well as HIV infections are endemic in sub Saharan Africa. This was a retrospective cohort study of 19 408 adults who were recruited between June 2004 and December 2010 in the AIDS Prevention Initiative in Nigeria in Nigeria programme at Jos University Teaching Hospital. Serological assays, including HBV surface antigen (HBsAg) and hepatitis C antibody were used to categorise hepatitis status of the patients. HBsAg was determined using enzyme immunoassay (EIA) (Monolisa HBsAg Ultra3; Bio-Rad). HCV antibody was tested using third generation EIA (DIA.PRO Diagnostic, Bioprobes srl, Milan, Italy). HIV RNA levels were measured using Roche COBAS Amplicor HIV-1 monitor test version 1.5 (Roche Diagnostics, GmbH, Mannheim, Germany) with a detection limit of 400 copies/mL. Flow cytometry was used to determine CD4+ cell count (Partec, GmbH Munster, Germany). Comparison of categorical and continuous variables were achieved using Pearson's chi(2) and Kruskal Wallis tests respectively, on MedCalc for Windows, version 9.5.0.0 (MedCalc Software, Mariakerke, Belgium). RESULTS: With an overall hepatitis screening rate of over 90% for each virus; HBV, HCV and HBV/HCV were detected in 3162 (17.8%), 1983 (11.3%) and 453 (2.5%) HIV infected adults respectively. The rate of liver disease was low, but highest among HIV mono-infected patients (29, 0.11%), followed by HBV co-infected patients (15, 0.08%). Patients with HBV co-infection and triple infection had higher log(10) HIV RNA loads (HBV: 4.6 copies/mL vs HIV only: 4.5 copies/mL, P < 0.0001) and more severe immune suppression (HBV: 645, 55.4%; HBV/HCV: 97, 56.7%) prior to initiation of HAART compared to HIV mono-infected patients (1852, 48.6%) (P < 0.0001). Of 3025 patients who were 4.4 years on HAART and whose CD4 cell counts results at baseline and end of follow up were available for analyses, CD4 increase was significantly lower in those with HBV co-infection (HBV: 144 cells/mm(3); HBV/HCV: 105 cells/mm(3)) than in those with HCV co-infection (165 cells/mm(3)) and HIV mono-infection (150 cells/mm(3)) (P = 0.0008). CONCLUSION: High rates of HBV and HCV infections were found in this HIV cohort. CD4 recovery was significantly diminished in patients with HBV co-infection. (c) 2013 Baishideng. All rights reserved.
引用
收藏
页码:1602 / 1610
页数:9
相关论文
共 33 条
[1]  
Adesina O, 2010, Afr J Med Med Sci, V39, P305
[2]   Clinical characteristics and predictors of mortality in hospitalized HIV-infected Nigerians [J].
Agaba, Patricia A. ;
Digin, Eunice ;
Makai, Rahila ;
Apena, Labake ;
Agbaji, Oche O. ;
Idoko, John A. ;
Murphy, Rob ;
Kanki, Phyllis .
JOURNAL OF INFECTION IN DEVELOPING COUNTRIES, 2011, 5 (05) :377-382
[3]  
Ajayi EA, 2011, PAN AFR MED J, V9
[4]   Anti-hepatitis B virus efficacy of tendovir disoproxil fumarate in HIV-infected patients [J].
Benhamou, Y ;
Fleury, H ;
Trimoulet, P ;
Pellegrin, I ;
Urbinelli, R ;
Katlama, C ;
Rozenbaum, W ;
Le Teuff, G ;
Trylesinski, A ;
Piketty, C .
HEPATOLOGY, 2006, 43 (03) :548-555
[5]   Hepatitis B and C infection and liver disease trends among human immunodeficiency virus-infected individuals [J].
Buskin, Susan E. ;
Barash, Elizabeth A. ;
Scott, John D. ;
Aboulafia, David M. ;
Wood, Robert W. .
WORLD JOURNAL OF GASTROENTEROLOGY, 2011, 17 (14) :1807-1816
[6]   Epidemiology of Hepatitis B Virus Infection in a US Cohort of HIV-Infected Individuals during the Past 20 Years [J].
Chun, Helen M. ;
Fieberg, Ann M. ;
Hullsiek, Katherine Huppler ;
Lifson, Alan R. ;
Crum-Cianflone, Nancy F. ;
Weintrob, Amy C. ;
Ganesan, Anuradha ;
Barthel, Robert V. ;
Bradley, William P. ;
Agan, Brian K. ;
Landrum, Michael L. .
CLINICAL INFECTIOUS DISEASES, 2010, 50 (03) :426-436
[7]   Temporal Analysis of Early Immune Responses in Patients With Acute Hepatitis B Virus Infection [J].
Dunn, Claire ;
Peppa, Dimitra ;
Khanna, Pooja ;
Nebbia, Gaia ;
Jones, Meleri ;
Brendish, Nathan ;
Lascar, R. Monica ;
Brown, David ;
Gilson, Richard J. ;
Tedder, Richard J. ;
Dusheiko, Geoffrey M. ;
Jacobs, Michael ;
Klenerman, Paul ;
Maini, Mala K. .
GASTROENTEROLOGY, 2009, 137 (04) :1289-1300
[8]  
Egah D. Z., 2007, Eastern Mediterranean Health Journal, V13, P961
[9]   Cancer risk in people infected with human immunodeficiency virus in the United States [J].
Engels, Eric A. ;
Biggar, Robert J. ;
Hall, H. Irene ;
Cross, Helene ;
Crutchfield, Allison ;
Finch, Jack L. ;
Griggs, Rebecca ;
Hylton, Tara ;
Pawlish, Karen S. ;
McNeel, Timothy S. ;
Goedert, James J. .
INTERNATIONAL JOURNAL OF CANCER, 2008, 123 (01) :187-194
[10]   The role of triple infection with hepatitis B virus, hepatitis C virus, and human immunodeficiency virus (HIV) type-1 on CD4+ lymphocyte levels in the highly HIV infected population of North-Central Nigeria [J].
Forbi, J. C. ;
Gabadi, S. ;
Alabi, R. ;
Iperepolu, H. O. ;
Pam, C. R. ;
Entonu, P. E. ;
Agwale, S. M. .
MEMORIAS DO INSTITUTO OSWALDO CRUZ, 2007, 102 (04) :535-537